Patents Assigned to Shandong Linghai Biotechnology Co., Ltd.
  • Patent number: 11840518
    Abstract: The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV Mpro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: December 12, 2023
    Assignee: Shandong Linghai Biotechnology Co., Ltd.
    Inventors: Dayong Shi, Xiangqian Li, Xin Wang, Feng Xu
  • Patent number: 11752133
    Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: September 12, 2023
    Assignee: SHANDONG LINGHAI BIOTECHNOLOGY CO., LTD.
    Inventors: Dayong Shi, Xiangqian Li, Xin Wang, Jinbo Yang, Feng Xu, Rong Zhang
  • Publication number: 20220363644
    Abstract: The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV Mpro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.
    Type: Application
    Filed: July 21, 2022
    Publication date: November 17, 2022
    Applicant: Shandong Linghai Biotechnology Co., Ltd.
    Inventors: Dayong Shi, Xiangqian Li, Xin Wang, Feng Xu